ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

Kwekkeboom, Dirk Jan; Krenning, Eric; Lebtahi, Rachida; Komminoth, Paul; Kos-Kudla, Beata; de Herder, Wouter; Annibale, Bruno; Arnold, Rudolf; Bajetta, Emilio; Barkmanova, Jaroslava; Chen, Yuan Jia; Costa, Frederico; Couvelard, Anne; Davar, Joseph; Delle Fave, Gianfranco; Eriksson, Barbro; Falconi, Massimo; Ferone, Diego; Gross, David; Grossman, Ashley Barry; Gustafsson, Björn; Hyrdel, Rudolf; Ivan, Diana; Kaltsas, Gregory; Kianmanesh, Reza; Knigge, Ulrich Peter; Lewington, Val; McNicol, Anne Marie; Mitry, Emmanuel; Nilsson, Ola; O'Toole, Dermot; O'Connor, Juan Manuel; Pape, Ulrich Frank; Papotti, Mauro; Pavel, Marianne; Perren, Aurel; Platania, Marco; Rindi, Guido; Ruszniewski, Philippe; Salazar, Ramon; Scarpa, Aldo; Scheidhauer, Klemens; Scoazec, Jean Yves; Sundin, Anders; Szpak, Waldemar; Taal, Babs; Vitek, Pavel; Vullierme, Marie Pierre; Wiedenmann, Bertram

doi:10.1159/000225951

The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT. This guideline also makes recommendations on what minimal patient, tumor, and treatment outcome characteristics should be reported for PRRT in order to make comparisons between studies possible. It is not this guideline's aim to give specific recommendations on the use of specific radiolabeled somatostatin analogs for PRRT because different analogs are being used, and their availability depends on national law and local permissions.

Additional Metadata
Keywords	1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid, Carcinoids, GEPNET, Neuroendocrine tumors, Radiolabeled somatostatin analogues, cancer radiotherapy, clinical trial, comparative study, conference paper, drug dose comparison, drug dose escalation, human, lutetium 177, multiple cycle treatment, neuroendocrine tumor, octreother, octreotide[3 tyrosine], pentetreotide in 111, peptide, peptide receptor radionuclide therapy, practice guideline, priority journal, radioisotope, somatostatin derivative, treatment duration, treatment outcome, unclassified drug, yttrium 90
Persistent URL	doi.org/10.1159/000225951, hdl.handle.net/1765/17636
Journal	Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Kwekkeboom, D.J, Krenning, E.P, Lebtahi, R, Komminoth, P, Kos-Kudla, B, de Herder, W.W, … Wiedenmann, B. (2009). ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. In Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships (Vol. 90, pp. 220–226). doi:10.1159/000225951

Full Text ( Final Version )

ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

Publication

Publication

About

ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

Publication

Publication

Workflow

Workflow

Add Content